B+
Overall grade
B
Financial quality
The sleeper story is commercial execution, not clinical data - Ed's comment that mid-single digit market share funds operations implies $7-10M+ pricing per patient, and they're building teams NOW for 2027 launch. The obvious regulatory drama obscures that MAGNITUDE-2 restart is on track and HAE timelines accelerated. The binding constraint is FDA bandwidth on MAGNITUDE hold, not safety data. Most revealing quote: 'A little bit goes a long way for a company our size' - they're betting everything on HAE commercial success. My view changes if MAGNITUDE hold extends past mid-2026 or if HAE market research enthusiasm doesn't translate to real physician adoption.
The 30-second version
- The sleeper story: Commercial readiness sprint is quietly defining success more than clinical data
- The obvious headline: MAGNITUDE hold drama BUT real story is MAGNITUDE-2 restart timing
- The hidden risk: Market research numbers sound too good to be true
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Cash Position | $669.9M Q3 vs $861.7M Q3 2024 | $605.1M Q4 vs $861.7M Q4 2024 |
| Collaboration Revenue | $13.8M Q3 vs $9.1M Q3 2024 | $23M Q4 vs $12.9M Q4 2024 |
| R&D Expenses | $94.7M Q3 vs $123.4M Q3 2024 | $88.7M Q4 vs $116.9M Q4 2024 |
| Net Loss | $101.3M Q3 vs $135.7M Q3 2024 | $95.8M Q4 vs $128.9M Q4 2024 |
| Stock-Based Compensation | $19.6M Q3 total | $16.7M Q4 total |
| G&A Expenses | $30.5M Q3 | $33.1M Q4 |
| MAGNITUDE Enrollment | 650+ patients enrolled by October hold | 650+ patients still on study during hold |
| MAGNITUDE-2 Enrollment | 47 patients enrolled before hold | Target increased to 60 patients |
Accountability tracked
8 new promises made5 narrative shifts flagged6 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →